
Braveheart Bio
BRVEPro trackingBraveheart Bio, Inc. · Nasdaq · Cardiovascular biotechnology · Research source · 424B4 · Research as of 2026/08/06 · Latest filing · 10-Q · 2026-11-10 SEC ↗ · SEC checked 2026-11-21
Saved research available · 424B4
Braveheart Bio priced its IPO at $18.00 per share for 21.25 million shares, with expected net proceeds of approximately $351.2 million before any overallotment exercise.
Updates and this research have separate source dates; newer facts do not silently replace earlier conclusions.
Newly listed — review valuation, deal quality and post-IPO supply before acting
A clinical-stage developer of therapies for hypertrophic cardiomyopathy and other cardiovascular diseases. The IPO priced at $18.00 and raised $382.50M.
Full source-backed summary
A clinical-stage developer of therapies for hypertrophic cardiomyopathy and other cardiovascular diseases. The IPO priced at $18.00 and raised $382.50M. The latest market-value reference is $1.77B; reported revenue is Pre-revenue and net result is $(80.23M). The offer figures are reconciled to the final prospectus.
- Business and development direction
A clinical-stage developer of therapies for hypertrophic cardiomyopathy and other cardiovascular diseases.
Current business Cardiovascular biotechnology100%
Future development Future direction not yet disclosed
Key risks
Risk 1
Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.
Risk 2
The latest reported period remains loss-making.
Risk 3
The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | This saved report has no compatible source inputs for this calculation. Open filing ↗ |
| # | Institution | Underwriting allocation | Ratio · calculated | Shares |
|---|---|---|---|---|
| 1 | Goldman Sachs & Co. LLC | 27.50% | 5,843,750 shares | |
| 2 | Jefferies LLC | 27.50% | 5,843,750 shares | |
| 3 | TD Securities (USA) LLC | 20.00% | 4,250,000 shares | |
| 4 | Stifel, Nicolaus & Company, Incorporated | 14.00% | 2,975,000 shares | |
| 5 | Cantor Fitzgerald & Co. | 11.00% | 2,337,500 shares |
Ratio = institution commitment ÷ complete source-table total (21,250,000 shares) × 100.
Underwriting terms
| Measure | Reported value | Unit |
|---|---|---|
| Underwriting discount per share | $1.26 | $ / share |
| Total underwriting discount | $26,775,000 | $ |
Source and calculation
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 4 row 4; source 6415:12145; SHA256 2b65ad2ca8cf79c1c0f71693026afbd435c3c683ee199559aed11c6ab5246563 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 4 row 4; source 6415:12145; SHA256 2b65ad2ca8cf79c1c0f71693026afbd435c3c683ee199559aed11c6ab5246563 ↗IPO CAPITAL QUALITY
Basis and evidence
No estimate is substituted for missing offer terms.
Capital quality is not yet quantifiable from the filed terms. IPO177 will calculate it when primary/secondary shares, fees and net proceeds are all disclosed.
Offering structure
| Measure | Reported value | Unit |
|---|---|---|
| Shares offered | 21,250,000 | Shares |
| Offering price | $18 | $ / share |
| Gross offering amount | $382,500,000 | $ |
Source and calculation
Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
SEC table 9 row 2; source 145898:152477; SHA256 28b39d93507c550c6ce73de8a221ffe4ab469ceeacd284d4c535abc2e212b8d2 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 4 row 3; source 6415:12145; SHA256 2b65ad2ca8cf79c1c0f71693026afbd435c3c683ee199559aed11c6ab5246563 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 4 row 3; source 6415:12145; SHA256 2b65ad2ca8cf79c1c0f71693026afbd435c3c683ee199559aed11c6ab5246563 ↗Proceeds and intended uses
| Measure | Reported value | Unit |
|---|---|---|
| Issuer proceeds before expenses | $355,725,000 | $ |
Source and calculation
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 4 row 5; source 6415:12145; SHA256 2b65ad2ca8cf79c1c0f71693026afbd435c3c683ee199559aed11c6ab5246563 ↗Dilution and valuation
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Base post-offer valuation | ≈ 73.1528M | ≈ $1.3168B | |
| Post-offer shares — base/no option | 73,152,838 | — | |
| Post-offer shares — full option | 76,340,338 | — | |
| Shares offered | 21,250,000 | — | |
| Offering price | — | $18 | |
| Gross offering amount | — | $382,500,000 |
Basis and evidence ↗
Prospectus share summary; Common stock to be outstanding immediately after this offering; 73,152,838 shares (or 76,340,338 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Prospectus share summary; Common stock to be outstanding immediately after this offering; 73,152,838 shares (or 76,340,338 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 73,152,838 shares (or 76,340,338 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Offering price: $18
Exact input · Post-offer shares — base/no option: 73,152,838
Prospectus share summary; Common stock to be outstanding immediately after this offering; 73,152,838 shares (or 76,340,338 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — full option: 76,340,338
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 73,152,838 shares (or 76,340,338 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 73,152,838 shares (or 76,340,338 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Prospectus share summary; Common stock to be outstanding immediately after this offering; 73,152,838 shares (or 76,340,338 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 73,152,838 shares (or 76,340,338 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — base/no option: 73,152,838
Exact input · Offering price: $18
Share-count comparison
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Source ↗IPO valuation scenario simulator
Offering completion · $18 × ≈ 73.1528M shares · Final
Source and calculation ↗
Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.
Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.
Equity value is the exact product of the selected compatible per-share price and whole-issuer post-offer count.
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.
The exact selected base supports transparent hypothetical price/share changes; it is not a forecast or tradable float.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
These saved displays are not verified valuation inputs. Their stage, precision and assumptions have not been established by the current source.
IPO price · 21.250M · $382.50M · $18.00
Latest shares outstanding · 64.17M · $1.77B · Market snapshot
Revenue reference · — · Pre-revenue · —
Net-result reference · — · $(80.23M) · Loss-making
$18 × 73,152,838 = $1,316,751,084 [summary-table-9-base-6-price, summary-table-9-base-6-post]
Exact calculation · Derived whole-issuer equity value: $1,316,751,084
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Comparable ownership figures across stages are unavailable in this report. See Control for holdings on their disclosed basis. Open filing ↗ |
Latest available filing
- Economic
- ~33.1%*
- As of
- 2026/08/06
Relationship filters
Select for details · Braveheart Bio
Holdings and voting rights
Holder groups may overlap; these rows are not an additive ownership partition.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| AH Bio Fund IV, L.P.Beneficial shares | 9,132,420 | — | — | Before Offering; Number of Shares of Common Stock Beneficially Owned |
| AH Bio Fund IV, L.P.Beneficial shares | 9,132,420 | — | — | After Offering; Number of Shares Beneficially Owned |
| Entities affiliated with ForbionBeneficial shares | 18,226,024 | — | — | Before Offering; Number of Shares of Common Stock Beneficially Owned |
| Entities affiliated with ForbionBeneficial shares | 18,226,024 | — | — | After Offering; Number of Shares Beneficially Owned |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd.Beneficial shares | 7,420,091 | — | — | Before Offering; Number of Shares of Common Stock Beneficially Owned |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd.Beneficial shares | 7,420,091 | — | — | After Offering; Number of Shares Beneficially Owned |
| Orbimed Private Investments IX, LPBeneficial shares | 10,235,159 | — | — | Before Offering; Number of Shares of Common Stock Beneficially Owned |
| Orbimed Private Investments IX, LPBeneficial shares | 10,235,159 | — | — | After Offering; Number of Shares Beneficially Owned |
| ES Braveheart Aggregator, L.P.Beneficial shares | 3,424,657 | — | — | Before Offering; Number of Shares of Common Stock Beneficially Owned |
| ES Braveheart Aggregator, L.P.Beneficial shares | 3,424,657 | — | — | After Offering; Number of Shares Beneficially Owned |
| Frazier Life Sciences Public Fund, L.P.Beneficial shares | 3,424,657 | — | — | Before Offering; Number of Shares of Common Stock Beneficially Owned |
| Frazier Life Sciences Public Fund, L.P.Beneficial shares | 3,424,657 | — | — | After Offering; Number of Shares Beneficially Owned |
| AH Bio Fund IV, L.P.Beneficial ownership | — | 13.9%Beneficial | — | Before Offering; Percentage of Shares Beneficially Owned |
| AH Bio Fund IV, L.P.Beneficial ownership | — | 10.5%Beneficial | — | After Offering; Percentage of Shares Beneficially Owned |
| Entities affiliated with ForbionBeneficial ownership | — | 27.8%Beneficial | — | Before Offering; Percentage of Shares Beneficially Owned |
| Entities affiliated with ForbionBeneficial ownership | — | 21%Beneficial | — | After Offering; Percentage of Shares Beneficially Owned |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd.Beneficial ownership | — | 11.3%Beneficial | — | Before Offering; Percentage of Shares Beneficially Owned |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd.Beneficial ownership | — | 8.5%Beneficial | — | After Offering; Percentage of Shares Beneficially Owned |
| Orbimed Private Investments IX, LPBeneficial ownership | — | 15.6%Beneficial | — | Before Offering; Percentage of Shares Beneficially Owned |
| Orbimed Private Investments IX, LPBeneficial ownership | — | 11.8%Beneficial | — | After Offering; Percentage of Shares Beneficially Owned |
| ES Braveheart Aggregator, L.P.Beneficial ownership | — | 5.2%Beneficial | — | Before Offering; Percentage of Shares Beneficially Owned |
| ES Braveheart Aggregator, L.P.Beneficial ownership | — | 3.9%Beneficial | — | After Offering; Percentage of Shares Beneficially Owned |
| Frazier Life Sciences Public Fund, L.P.Beneficial ownership | — | 5.2%Beneficial | — | Before Offering; Percentage of Shares Beneficially Owned |
| Frazier Life Sciences Public Fund, L.P.Beneficial ownership | — | 3.9%Beneficial | — | After Offering; Percentage of Shares Beneficially Owned |
| Travis Murdoch, M.D., Chief Executive Officer, President and DirectorBeneficial shares | 8,250,304 | — | — | Before Offering; Number of Shares of Common Stock Beneficially Owned |
| Travis Murdoch, M.D., Chief Executive Officer, President and DirectorBeneficial shares | 8,250,304 | — | — | After Offering; Number of Shares Beneficially Owned |
| Michele Anderson, Chief Development OfficerBeneficial shares | 331,050 | — | — | Before Offering; Number of Shares of Common Stock Beneficially Owned |
| Michele Anderson, Chief Development OfficerBeneficial shares | 331,050 | — | — | After Offering; Number of Shares Beneficially Owned |
| J. Paul Rickey, Chief Financial OfficerBeneficial shares | 675,798 | — | — | Before Offering; Number of Shares of Common Stock Beneficially Owned |
| J. Paul Rickey, Chief Financial OfficerBeneficial shares | 675,798 | — | — | After Offering; Number of Shares Beneficially Owned |
| Christopher ViehbacherBeneficial shares | 676,524 | — | — | Before Offering; Number of Shares of Common Stock Beneficially Owned |
| Christopher ViehbacherBeneficial shares | 676,524 | — | — | After Offering; Number of Shares Beneficially Owned |
| Jason Coloma, Ph.D., M.B.A.Beneficial shares | 1,100,456 | — | — | Before Offering; Number of Shares of Common Stock Beneficially Owned |
| Jason Coloma, Ph.D., M.B.A.Beneficial shares | 1,100,456 | — | — | After Offering; Number of Shares Beneficially Owned |
| David Malek, M.B.A.Beneficial shares | 1,009,131 | — | — | Before Offering; Number of Shares of Common Stock Beneficially Owned |
| David Malek, M.B.A.Beneficial shares | 1,009,131 | — | — | After Offering; Number of Shares Beneficially Owned |
| Travis Murdoch, M.D., Chief Executive Officer, President and DirectorBeneficial ownership | — | 12.6%Beneficial | — | Before Offering; Percentage of Shares Beneficially Owned |
| Travis Murdoch, M.D., Chief Executive Officer, President and DirectorBeneficial ownership | — | 9.5%Beneficial | — | After Offering; Percentage of Shares Beneficially Owned |
| Michele Anderson, Chief Development OfficerBeneficial ownership | — | 0.4%Beneficial | — | After Offering; Percentage of Shares Beneficially Owned |
| J. Paul Rickey, Chief Financial OfficerBeneficial ownership | — | 1%Beneficial | — | Before Offering; Percentage of Shares Beneficially Owned |
| J. Paul Rickey, Chief Financial OfficerBeneficial ownership | — | 0.8%Beneficial | — | After Offering; Percentage of Shares Beneficially Owned |
| Christopher ViehbacherBeneficial ownership | — | 1%Beneficial | — | Before Offering; Percentage of Shares Beneficially Owned |
| Christopher ViehbacherBeneficial ownership | — | 0.8%Beneficial | — | After Offering; Percentage of Shares Beneficially Owned |
| Jason Coloma, Ph.D., M.B.A.Beneficial ownership | — | 1.7%Beneficial | — | Before Offering; Percentage of Shares Beneficially Owned |
| Jason Coloma, Ph.D., M.B.A.Beneficial ownership | — | 1.3%Beneficial | — | After Offering; Percentage of Shares Beneficially Owned |
| David Malek, M.B.A.Beneficial ownership | — | 1.5%Beneficial | — | Before Offering; Percentage of Shares Beneficially Owned |
| David Malek, M.B.A.Beneficial ownership | — | 1.2%Beneficial | — | After Offering; Percentage of Shares Beneficially Owned |
| All executive officers and directors as a group (10 persons)Beneficial ownership | — | 18.4%Beneficial | — | Before Offering; Percentage of Shares Beneficially Owned |
| All executive officers and directors as a group (10 persons)Beneficial shares | 12,043,263 | — | — | Before Offering; Number of Shares of Common Stock Beneficially Owned |
| All executive officers and directors as a group (10 persons)Beneficial shares | 12,043,263 | — | — | After Offering; Number of Shares Beneficially Owned |
| All executive officers and directors as a group (10 persons)Beneficial ownership | — | 13.9%Beneficial | — | After Offering; Percentage of Shares Beneficially Owned |
| our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective affiliatesOwnership as disclosed | — | approximately 73.6%Beneficial | — | Source statement; approximately ; source predicate: will beneficially own; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any potential purchases by such persons in this offering or (ii) issuance of options to be grante; source scope: of our outstanding common stock (assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any potential p; not an additive ownership partition |
| Entities affiliated with ForbionOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| HengruiOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| common stockper-share voting rights | — | — | 1 vote per shareVotes per share | Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicable |
Source and calculation ↗
Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: AH Bio Fund IV, L.P.(1)
Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: AH Bio Fund IV, L.P.(1)
Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: Entities affiliated with Forbion(2)
Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: Entities affiliated with Forbion(2)
Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: Jiangsu Hengrui Pharmaceuticals Co., Ltd.(3)
Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: Jiangsu Hengrui Pharmaceuticals Co., Ltd.(3)
Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: Orbimed Private Investments IX, LP(4)
Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: Orbimed Private Investments IX, LP(4)
Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: ES Braveheart Aggregator, L.P.(5)
Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: ES Braveheart Aggregator, L.P.(5)
Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: Frazier Life Sciences Public Fund, L.P.(6)
Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: Frazier Life Sciences Public Fund, L.P.(6)
Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: AH Bio Fund IV, L.P.(1)
Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: AH Bio Fund IV, L.P.(1)
Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: Entities affiliated with Forbion(2)
Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: Entities affiliated with Forbion(2)
Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: Jiangsu Hengrui Pharmaceuticals Co., Ltd.(3)
Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: Jiangsu Hengrui Pharmaceuticals Co., Ltd.(3)
Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: Orbimed Private Investments IX, LP(4)
Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: Orbimed Private Investments IX, LP(4)
Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: ES Braveheart Aggregator, L.P.(5)
Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: ES Braveheart Aggregator, L.P.(5)
Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: Frazier Life Sciences Public Fund, L.P.(6)
Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: Frazier Life Sciences Public Fund, L.P.(6)
Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: Travis Murdoch, M.D., Chief Executive Officer, President and Director(7)
Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: Travis Murdoch, M.D., Chief Executive Officer, President and Director(7)
Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: Michele Anderson, Chief Development Officer(8)
Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: Michele Anderson, Chief Development Officer(8)
Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: J. Paul Rickey, Chief Financial Officer(9)
Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: J. Paul Rickey, Chief Financial Officer(9)
Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: Christopher Viehbacher(10)
Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: Christopher Viehbacher(10)
Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: Jason Coloma, Ph.D., M.B.A.(11)
Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: Jason Coloma, Ph.D., M.B.A.(11)
Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: David Malek, M.B.A.(12)
Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: David Malek, M.B.A.(12)
Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: Travis Murdoch, M.D., Chief Executive Officer, President and Director(7)
Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: Travis Murdoch, M.D., Chief Executive Officer, President and Director(7)
Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: Michele Anderson, Chief Development Officer(8)
Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: J. Paul Rickey, Chief Financial Officer(9)
Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: J. Paul Rickey, Chief Financial Officer(9)
Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: Christopher Viehbacher(10)
Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: Christopher Viehbacher(10)
Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: Jason Coloma, Ph.D., M.B.A.(11)
Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: Jason Coloma, Ph.D., M.B.A.(11)
Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: David Malek, M.B.A.(12)
Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: David Malek, M.B.A.(12)
Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: All executive officers and directors as a group (10 persons)(13)
Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition
Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: All executive officers and directors as a group (10 persons)(13)
Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: All executive officers and directors as a group (10 persons)(13)
Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition
Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: All executive officers and directors as a group (10 persons)(13)
Source statement; approximately ; source predicate: will beneficially own; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any potential purchases by such persons in this offering or (ii) issuance of options to be grante; source scope: of our outstanding common stock (assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any potential p; not an additive ownership partition
Following the completion of this offering, our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective affiliates will beneficially own approximately 73.6% of our outstanding common stock (assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any potential purchases by such persons in this offering or (ii) issuance of options to be granted to certain of our employees and non-employee directors upon pricing of this offering). As a result, these persons, acting together, would be able to control all matters requiring stockholder approval, including the election and removal of directors, any merger, consolidation, sale of all or substantially all of our assets, or other significant corporate transactions.
Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
(3)Consists of 40,000,000 shares of Series A preferred stock held by Forbion Growth Opportunities Fund III Coöperatief U.A. and 35,000,000 shares of Series A preferred stock held by Forbion Ventures Fund VII Coöperatief U.A. Entities affiliated with Forbion beneficially own more than 5% of our outstanding capital stock.
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
In September 2025, we entered into an Exclusive License Agreement (the “Exclusive License Agreement”) with Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”). Pursuant to the terms of the Exclusive License Agreement, Hengrui received an upfront payment of $58.2 million, comprised of $32.5 million in cash and 32,500,000 shares of non-voting Series A preferred stock with an aggregate estimated fair value of $25.7 million. A technology transfer milestone under the Exclusive License Agreement was completed in December 2025, which resulted in an accrual of $3.0 million as of December 31, 2025, which was paid as of March 31, 2026. A manufacturing technology transfer milestone under the Exclusive License Agreement was completed in March 2026, which resulted in accounts payable of $6.0 million as of March 31, 2026, which was paid in May 2026. Hengrui beneficially owns more than 5% of our outstanding capital stock. See the section titled “Business—Hengrui License Agreement” for additional information.
Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicable
Except as otherwise expressly provided in our second amended and restated certificate of incorporation or as required by applicable law, on any matter that is submitted to a vote by our stockholders, holders of our common stock are entitled to one vote per share of common stock, including for the election of directors. Source context: The following description of our capital stock and certain provisions of our second amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to the second amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and the amended and restated bylaws, which became effective upon the effectiveness of the registration statement of which this prospectus forms a part. Copies of these documents have been filed with the SEC as exhibits to our registration statement, of which this prospectus forms a part. The descriptions of the common stock and preferred stock reflect changes to our capital structure that will be in effect on the completion of this offering.
Saved control snapshot
The dated saved report retains its own figures and assumptions. These strings are not new calculation inputs.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| Existing holdersMajor ownership group | — | ~66.9%* | — | |
| Other disclosed classesMajor ownership group | — | See filing | — | |
| IPO sharesPublic / new investors | — | 21.250M | — |
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
IPO shares are immediately tradable; later supply depends on the final lock-up, option and resale-registration terms.
- Initial float
- 21.250M
- Restricted / potential supply
- 64.17M
- Multiple
- See filing
- Increase
- See filing
Share supply
Source lock-up conditions
Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| The company and its officers, directors, and holders of substantially all of the company’s common stockAfter date of this prospectus · Source conditions apply | 180 days |
Source and calculation
The company and its officers, directors, and holders of substantially all of the company’s common stock have agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of common stock (collectively, the "Lock-Up Securities") during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of the representatives. See “Shares Eligible for Future Sale” for a discussion of certain transfer restrictions.
SEC lock-up paragraph; source 2619937:2621019; SHA256 c7a9c6d4e03546b51462e0ed4d40f553784215bf3ed284b47d8b22f932db8ffc ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
Milestones and unconfirmed releases
| Holder / event | Term / date | Conditions |
|---|---|---|
| Over-allotment window | Post-listing See filing · Additional shares only if exercised | Over-allotment window · Additional shares only if exercised |
| Insider resale eligibility | Holder-specific See 424B · Existing-holder supply | Insider resale eligibility · Existing-holder supply |
Basis and evidence
Over-allotment window · Additional shares only if exercised
Lock-up / shares eligible for future sale ↗Insider resale eligibility · Existing-holder supply
Lock-up / shares eligible for future sale ↗Financial quality
| Calculation | Reported value |
|---|---|
| Cash and cash equivalents2025-12-31 | $89,161,000 |
| Current assets2025-12-31 | $89,280,000 |
| Total assets2025-12-31 | $89,350,000 |
| Current liabilities2025-12-31 | $5,242,000 |
| Total liabilities2025-12-31 | $5,333,000 |
| Total equity / (deficit)2025-12-31 | ($65,872,000) |
| Net income / (loss)FY2025 | ($66,052,000) |
| Cash and cash equivalents2026-03-31 · Unaudited | $80,576,000 |
| Cash and cash equivalents2025-12-31 · Unaudited | $89,161,000 |
| Current assets2026-03-31 · Unaudited | $81,072,000 |
| Current assets2025-12-31 · Unaudited | $89,280,000 |
| Total assets2026-03-31 · Unaudited | $81,878,000 |
| Total assets2025-12-31 · Unaudited | $89,350,000 |
| Current liabilities2026-03-31 · Unaudited | $10,002,000 |
| Current liabilities2025-12-31 · Unaudited | $5,242,000 |
| Total liabilities2026-03-31 · Unaudited | $10,385,000 |
| Total liabilities2025-12-31 · Unaudited | $5,333,000 |
| Total equity / (deficit)2026-03-31 · Unaudited | ($78,392,000) |
| Total equity / (deficit)2025-12-31 · Unaudited | ($65,872,000) |
| Net income / (loss)3M ended 2026-03-31 · Unaudited | ($14,280,000) |
| Net income / (loss)3M ended 2025-03-31 · Unaudited | ($99,000) |
Basis and evidence
Saved snapshot — period not verified
These saved figures have no verified reporting period or currency basis. They are excluded from statement comparisons and calculations.
Financial quality
| Calculation | Reported value |
|---|---|
| Revenue | Pre-revenue |
| Net resultLatest reported | $(80.23M) |
| Market-value referencePost-listing snapshot | $1.77B |
| Shares outstandingLatest reported | 64.17M |
| Offer size21.250M | $382.50M |
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Financial review | Reported financial figures are shown above. A cash-runway estimate needs compatible cash-flow and funding assumptions. Open filing ↗ |
Baseline filing — comparison pending
No source-comparable material changes identified in this report.
Why it mattersChanges dilution, public float and potential supply.
Evidence · 424B4 · 2026/08/06Why it mattersChanges valuation, proceeds and first-day return assumptions.
Evidence · 424B4 · 2026/08/06424B4
• Final prospectus source verified
• Trading began on 2026-08-06 at $18.00
Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.
- Potential impact
- High
- Evidence
- 424B4 · 2026/08/06 ↗
The latest reported period remains loss-making.
- Potential impact
- High
- Evidence
- 424B4 · 2026/08/06 ↗
The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.
- Potential impact
- High
- Evidence
- 424B4 · 2026/08/06 ↗
Option exercise, employee equity and lock-up expiry can expand tradable supply.
- Potential impact
- Medium
- Evidence
- 424B4 · 2026/08/06 ↗
Sources and calculation notes
Final prospectus, offer price, listing date and headline financial evidence reconciled
View the filing's actual first page +
